Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Baxter
Daiichi Sankyo
Queensland Health
QuintilesIMS
Federal Trade Commission
Citi
Argus Health
Farmers Insurance

Generated: July 19, 2018

DrugPatentWatch Database Preview

Lupin Ltd Company Profile

« Back to Dashboard

What is the competitive landscape for LUPIN LTD, and when can generic versions of LUPIN LTD drugs launch?

LUPIN LTD has one hundred and sixteen approved drugs.

There is one US patent protecting LUPIN LTD drugs. There are fifteen tentative approvals on LUPIN LTD drugs.

There are two patent family members on LUPIN LTD drugs in two countries and two hundred and ten supplementary protection certificates in thirteen countries.

Drugs and US Patents for Lupin Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd LEVETIRACETAM levetiracetam TABLET, EXTENDED RELEASE;ORAL 091399-002 Sep 12, 2011 AB RX No No ➤ Sign Up ➤ Sign Up
Lupin Ltd PAROXETINE HYDROCHLORIDE paroxetine hydrochloride TABLET, EXTENDED RELEASE;ORAL 204134-003 Jan 20, 2017 AB RX No No ➤ Sign Up ➤ Sign Up
Lupin Ltd VALSARTAN valsartan TABLET;ORAL 201677-002 Jan 5, 2015 AB RX No No ➤ Sign Up ➤ Sign Up
Lupin Ltd FENOFIBRATE fenofibrate TABLET;ORAL 090856-002 Dec 23, 2011 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for LUPIN LTD drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03
➤ Subscribe for Oral Suspension 500 mg/5 mL ➤ Subscribe 2014-07-22

Non-Orange Book US Patents for Lupin Ltd

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,241,905 Pharmaceutical compositions of Cefixime ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Lupin Ltd Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00357 Netherlands ➤ Sign Up PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
315 Luxembourg ➤ Sign Up PRODUCT NAME: COMBINAISON COMPRENANT ALISKIREN,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE,ET AMLODIPINE,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE
0907 Netherlands ➤ Sign Up PRODUCT NAME: DEOXYCHOLINEZUUR NATRIUMZOUT
C0043 France ➤ Sign Up PRODUCT NAME: ROSUVASTATIN; NAT. REGISTRATION NO/DATE: NL 28 274 20030611; FIRST REGISTRATION: NL - 26872 20021106
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Daiichi Sankyo
Express Scripts
Medtronic
Accenture
Boehringer Ingelheim
McKinsey
Cantor Fitzgerald
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.